Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
The clonal immunoglobulin idiotype displayed on the surface of most malignant B cells is a patient- and tumour-specific antigen that can be used for therapeutic vaccination. Several studies have confirmed the biological efficacy of soluble protein idiotypic vaccination and two clinical trials have shown the clinical efficacy of this procedure. One study has demonstrated clinical benefit associated with idiotypic vaccination. However, three randomized clinical trials have recently failed to achieve their main end points for reasons that are probably unrelated to the vaccine. While scepticism towards this type of non-toxic medical intervention is mounting, such patient-specific treatments might yet see the light of day through better designed clinical trials.
Bendandi
Maurizio
M
Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain. mbendandi@unav.es
D019496:Cancer Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*
D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes
J Immunol. 2008 Sep 15;181(6):4131-40
18768870
Leuk Lymphoma. 2009 Jan;50(1):47-53
19152172
Mol Immunol. 2009 Jan;46(3):448-56
19046770
J Clin Invest. 2004 May;113(10):1498-510
15146248
N Engl J Med. 2004 Nov 18;351(21):2159-69
15548776
J Biol Chem. 2007 Mar 9;282(10):7405-15
17197448
Nature. 1975 Apr 24;254(5502):714-6
47617
J Clin Oncol. 2007 Feb 10;25(5):579-86
17242396
J Immunol. 1990 Aug 1;145(3):1029-36
2373859
N Engl J Med. 1992 Oct 22;327(17):1209-15
1406793
Expert Rev Vaccines. 2009 Jan;8(1):43-50
19093772
J Immunol. 1987 Jan 15;138(2):628-34
3491853
CA Cancer J Clin. 2008 Sep-Oct;58(5):305-17
18755938
Blood. 2004 Oct 1;104(7):1961-9
15191951
J Immunol. 1987 Feb 15;138(4):1289-96
3492546
J Clin Oncol. 2004 Dec 1;22(23):4717-24
15483014
N Engl J Med. 2003 Jun 26;348(26):2609-17
12826635
J Immunol Methods. 1986 May 1;89(1):61-72
3084658
Proc Natl Acad Sci U S A. 1971 Dec;68(12):3130-5
4108872
Blood. 1997 May 1;89(9):3129-35
9129015
J Clin Oncol. 2006 Jul 1;24(19):3107-12
16754937
Haematologica. 2004 May;89(5):541-6
15136216
J Clin Oncol. 1995 Jan;13(1):140-7
7799014
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10972-7
8855293
Br J Haematol. 2008 Jun;142(2):179-91
18422783
N Engl J Med. 1985 Jun 27;312(26):1653-8
3923351
N Engl J Med. 1985 Jun 27;312(26):1658-65
3923352
Blood. 2002 Apr 1;99(7):2562-8
11895794
Expert Rev Vaccines. 2004 Apr;3(2):163-70
15056042
Leukemia. 2000 Aug;14(8):1333-9
10942225
Blood. 2009 Jun 4;113(23):5743-6
19346494
Blood Rev. 2009 May;23(3):137-42
18951668
Leuk Lymphoma. 2009 Jan;50(1):1-2
19172492
J Natl Cancer Inst. 2006 Sep 20;98(18):1263-5
16985240
J Immunother. 2008 Apr;31(3):310-2
18317357
Haematologica. 2003 Dec;88(12):1438-40
14688006
Blood. 1998 Aug 15;92(4):1184-90
9694706
Nat Med. 2005 Sep;11(9):986-91
16116429
Nat Med. 1999 Oct;5(10):1171-7
10502821
Leuk Lymphoma. 2009 Jan;50(1):37-46
19125383
Eur Urol. 2000;37 Suppl 3:24-33
10828684
Proc Natl Acad Sci U S A. 1972 Jun;69(6):1540-4
4113870
J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301
16985248
Rev Recent Clin Trials. 2006 Jan;1(1):67-74
18393782
J Clin Oncol. 2009 Jun 20;27(18):3036-43
19414675
Blood. 2007 Feb 1;109(3):951-3
17032925
Crit Rev Oncol Hematol. 2004 Oct;52(1):1-7
15363462
J Natl Cancer Inst. 2003 Jun 18;95(12):845
12813164
Expert Rev Anticancer Ther. 2001 Jun;1(1):65-72
12113135
Vaccine. 2009 Jan 7;27(2):250-9
19000731